A biomarker is any measurable characteristic of your body that indicates what’s happening inside it. Your blood pressure, blood sugar level, cholesterol count, heart rate, and even a tumor visible on an MRI scan all qualify as biomarkers. The formal definition, established by the FDA and NIH, describes a biomarker as “a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention.” In practical terms, biomarkers are the numbers and signals doctors use to detect disease, track your health over time, and decide which treatments to try.
One important distinction: a biomarker is not about how you feel. Your fatigue, your pain level, your ability to walk up a flight of stairs are all meaningful, but they fall into a different category called clinical outcomes. Biomarkers are the objective, measurable data points that complement your subjective experience.
Everyday Biomarkers You Already Know
You’ve encountered biomarkers at virtually every doctor’s visit, even if you’ve never heard the term. The blood pressure cuff reading your nurse takes is a physiologic biomarker. A cholesterol panel from a blood draw gives molecular biomarkers. A chest X-ray produces a radiographic biomarker. These are all different types of the same basic concept: measurable signals that tell a story about your health.
One of the most widely used biomarkers is the HbA1c test, which measures the percentage of your red blood cells coated with glucose. Because red blood cells live about three months, this single number captures your average blood sugar over that entire period. A result below 5.7% is normal, 5.7% to 6.4% signals prediabetes, and 6.5% or higher indicates diabetes. That one number can trigger a diagnosis, guide medication choices, and track whether a treatment plan is working.
The Seven Categories of Biomarkers
Not all biomarkers serve the same purpose. The FDA recognizes seven distinct categories, each answering a different clinical question:
- Susceptibility/risk biomarkers identify whether you’re more likely to develop a disease before any symptoms appear. A genetic variant that raises your lifetime risk of breast cancer is one example.
- Diagnostic biomarkers confirm whether a disease is present. A blood test detecting specific proteins can distinguish one type of infection from another.
- Monitoring biomarkers track the status of a disease or the effect of a treatment over time. Regular blood sugar checks for someone with diabetes fall here.
- Prognostic biomarkers estimate how a disease is likely to progress, regardless of treatment. Certain tumor characteristics can indicate whether a cancer is slow-growing or aggressive.
- Predictive biomarkers help determine which treatment is most likely to work for a specific patient. This is a cornerstone of precision medicine.
- Pharmacodynamic (response) biomarkers show whether a treatment is having its intended biological effect in your body.
- Safety biomarkers flag whether a treatment is causing harm, such as liver enzyme levels that spike when a medication is toxic to the liver.
A single measurement can sometimes serve multiple roles. Blood pressure, for instance, acts as a diagnostic biomarker when it’s used to identify hypertension, a monitoring biomarker when it’s tracked over months, and a safety biomarker when a new medication might push it too low.
How Biomarkers Power Precision Medicine
Over the past two decades, biomarkers have transformed cancer treatment from a one-size-fits-all approach into something far more targeted. Tumors can now be tested for specific molecular features that predict whether a particular therapy will be effective. If a breast cancer tests positive for a protein called HER2, for example, treatments designed to target that protein become a strong option. If the test is negative, those same drugs would offer little benefit and only side effects.
This principle extends across oncology and increasingly into other fields. Biomarkers allow doctors to stratify patients into groups that will respond to a therapy and groups that won’t, sparing people from treatments unlikely to help them. The goal is individualized treatment: using the biological profile of your specific disease to choose the best path forward rather than relying on broad population averages.
From Lab Discovery to Clinical Use
A biomarker doesn’t go from a research finding to your doctor’s office overnight. The process involves multiple stages of validation. First, researchers must prove the biomarker can be measured reliably: that results are consistent across different labs, different technicians, and different days. This means demonstrating precision, accuracy, and stability of the samples being tested.
Next comes clinical validation, which answers the harder question: does this biomarker actually predict what we think it predicts? Researchers evaluate how well the biomarker’s levels correlate with disease activity, how accurately it reflects the impact of treatment, and whether changes in the biomarker represent clinically meaningful outcomes. The FDA requires evidence of sensitivity (how well it catches true cases), specificity (how well it avoids false alarms), and predictive value before a biomarker can be formally qualified for use in drug development decisions.
Biomarkers vs. Surrogate Endpoints
You may hear the term “surrogate endpoint” used alongside biomarkers, especially in the context of clinical trials. The two concepts are related but not identical. A surrogate endpoint is a biomarker that has been validated well enough to stand in for a clinical outcome in a trial. Clinical outcomes are the gold standard, because they directly measure what matters most: whether people feel better, function better, or live longer. But those outcomes can take years to observe.
When that wait is impractical, regulators sometimes accept a surrogate endpoint instead. Controlling blood pressure, for example, is a well-validated surrogate for preventing heart attacks and strokes. Some surrogate endpoints are classified as “reasonably likely” but not yet fully validated. Drugs approved on this basis through the FDA’s Accelerated Approval program must still prove their real-world clinical benefit in follow-up studies.
Digital Biomarkers and Wearable Technology
The definition of a biomarker is expanding beyond the lab. Digital biomarkers are health signals captured continuously by wearable devices, smartphones, and connected medical tools. A smartwatch tracking your heart rate variability, sleep quality, and daily step count is collecting biomarker data in real time, outside of any clinical setting.
This shift is already changing how clinical trials operate. In stroke recovery trials, wearable biosensors now gather real-time data on patient health between hospital visits, allowing researchers to track recovery more accurately and intervene earlier when problems arise. Continuous glucose monitors provide moment-by-moment blood sugar patterns in diabetes trials, offering far richer data than a single lab draw ever could. Newer efforts use smartphone-based cognitive assessments and voice analysis to detect subtle signs of cognitive impairment in cancer patients undergoing chemotherapy.
Researchers are also exploring what they call the “digital microenvironment,” where contextual signals like light exposure, sleep-wake rhythms, and environmental noise are captured through smart home devices. These ambient data points may eventually serve as biomarkers for mental health conditions, neurological diseases, and other areas where traditional lab tests fall short.